Journal
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Volume 62, Issue 2, Pages -Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.202214473
Keywords
Bioorthogonal Chemistry; Boron Dipyrromethene; Dual Receptor; Inverse Electron-Demand Diels-Alder Reaction; Photodynamic Therapy
Categories
Ask authors/readers for more resources
In this study, a novel dual receptor-mediated bioorthogonal activation approach was developed to enhance the tumor specificity of photodynamic therapy. By targeted delivery and specific activation of photosensitizers, the photodynamic action was confined to cancer cells that overexpress both the biotin receptor and epidermal growth factor receptor (EGFR).
Targeted delivery and specific activation of photosensitizers can greatly improve the treatment outcome of photodynamic therapy. To this end, we report herein a novel dual receptor-mediated bioorthogonal activation approach to enhance the tumor specificity of the photodynamic action. It involves the targeted delivery of a biotinylated boron dipyrromethene (BODIPY)-based photosensitizer, which is quenched in the native form by the attached 1,2,4,5-tetrazine unit, and an epidermal growth factor receptor (EGFR)-targeting cyclic peptide conjugated with a bicycle[6.1.0]non-4-yne moiety. Only for cancer cells that overexpress both the biotin receptor and EGFR, the two components can be internalized preferentially where they undergo an inverse electron-demand Diels-Alder reaction, leading to restoration of the photodynamic activity of the BODIPY core. By using a range of cell lines with different expression levels of these two receptors, we have demonstrated that this stepwise deliver-and-click approach can confine the photodynamic action on a specific type of cancer cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available